SpyGlass Posts $39.9M Net Loss in 2025, Maintains Liquidity to Fund Operations Through 2028
SGP is trading near its 52-week low of $22.41 (11% above the low).
Summary
SpyGlass Pharma reported a net loss of $39.9 million and a loss per share of $17.98 for the year ended December 31, 2025, as detailed in its 10-K filing. These financial results follow an earlier 8-K filing today where the company announced positive 12-month Phase 1/2 data for its BIM-IOL System. The losses are attributed to increased research and development spending, up 46% in 2025, and operational scaling to support expanded clinical programs, including two Phase 3 trials initiated in July 2025. While the net loss is substantial, the company stated that proceeds from its IPO and existing liquidity are expected to fund operations through 2028, providing critical stability for a clinical-stage biotech. Investors will monitor the progress of the ongoing Phase 3 trials and the company's ability to maintain its cash runway as it moves towards a potential 505(b)(2) NDA submission in 2028.
At the time of this announcement, SGP was trading at $24.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $839.6M. The 52-week trading range was $22.41 to $30.56. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.